Skip to content

Clinical observation of different acupoint prescriptions in the treatment of neck pain caused by cervical spondylosis in qi stagnation and blood stasis type

Clinical observation of different acupoint prescriptions in the treatment of neck pain caused by cervical spondylosis in qi stagnation and blood stasis type——Single blind randomized controlled trial

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900025413
Enrollment
Unknown
Registered
2019-08-26
Start date
2019-04-01
Completion date
Unknown
Last updated
2019-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cervical spondylosis

Interventions

Sponsors

Shanghai Shuguang Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) accord with the diagnostic criteria for cervical spondylosis; 2) caused by neck trauma or injury, stiff and pain neck with fixed pain points, the pain will intensified when move; often accompanied by limb numbness, pale red tongue with purple dark spots (or not), string or uneven pulse 3) Aged 18 to 65 years; 4) The course of neck pain >=12 weeks; 5)VAS 3 to 7 before treatment; 6) Have not taken any painkillers or glucocorticoids in the past 2 weeks; 7) Sign the informed consent form, volunteer to participate and cooperate with the researcher.

Exclusion criteria

Exclusion criteria: 1) Those who do not accord with the above inclusion criteria; 2) pregnant or lactating women; 3) cervical spondylotic myelopathy, or other indications for absolute surgery, must be treated surgically; 4) Those who have serious diseases such as cardiovascular, cerebrovascular, liver, kidney, hematopoietic, digestive system, or mental illness; 5) Have received cervical spondylosis-related treatment within 1 month, or have received other treatments that may affect the effector indicators of the study; 6) Can not correctly understand and fill out the various scales related to the research; 7) Reluctant to join the tester; 8) The investigator believes that it is not appropriate to participate in other situations in this study.

Design outcomes

Primary

MeasureTime frame
vas;

Secondary

MeasureTime frame
FDIX Force One;NPQ;NDI;SF-36;

Countries

China

Contacts

Public ContactBo Wang

Shanghai Shuguang Hospital

carloswb@163.com+86 13817734770

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026